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Docetaxel-based combination chemotherapy remains the predominant treatment for 
castration-resistant prostate cancer. However, taxane-related drug resistance and 
neurotoxicity have prompted us to develop substitute treatment strategies. Eg5 
(kinesin spindle protein), which is crucial for bipolar spindle formation and duplicated 
chromosome separation during the early phase of mitosis, has emerged as an 
attractive target for cancer chemotherapy. The aim of this study was to investigate the 
anticancer efficacy of S-(methoxytrityl)-L-cysteine [S(MeO)TLC], a novel Eg5 
inhibitor in prostate cancer. Eg5 expression was examined in human prostate cancer 
cell lines and tissue microarrays constructed from clinical specimens. 
Anti-proliferative activity of S(MeO)TLC in prostate cancer cells was assessed by a 
cell viability assay. The anticancer effect and inhibitory mechanism of S(MeO)TLC in 
prostate cancer cells was further explored by Hoechst staining, flow cytometry and 
immunofluorescence. In addition, the antitumor effect of S(MeO)TLC on 
subcutaneous xenograft models was assessed. Eg5 expression was identified in PC3, 
DU145 and LNCaP cells. More than half of prostate cancer clinical specimens 
displayed Eg5 expression. S(MeO)TLC exhibited more powerful anticancer activity 
in prostate cancer cells compared with the other four Eg5 inhibitors tested. 
S(MeO)TLC induced cell death after arresting dividing cells at mitosis with distinct 
monopolar spindle formation. S(MeO)TLC exhibited its significant inhibitory activity 
(P < 0.05) on subcutaneous xenograft models also through induction of mitotic arrest. 
We conclude that Eg5 is a good target for prostate cancer chemotherapy, and 
S(MeO)TLC is a potent promising anticancer agent in prostate cancer.  
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Introduction 
Prostate cancer is one of the most commonly diagnosed malignancies and the second 
highest cause of cancer death in American men, with an estimated 27 360 patients 
dying of castration-resistant prostate cancer (CRPC) in 2009 
1
. Furthermore, in recent 
years, there has been a more rapid increase in the incidence and mortality rates in 
Asian countries 
2
. Androgen deprivation therapy (ADT), including surgical 
orchiectomy and luteinizing hormone-releasing hormone agonists are the primary 
treatments for patients with advanced prostate cancer. These patients respond initially 
to ADT within 1–2 years, but eventually they progress to CRPC. Eventually CRPC 
develops followed by ADT after 1 to 2 years’ response time 3. Combination 
chemotherapy based on docetaxel is the standard treatment for patients with CRPC 
4,5
. 
However, no standard treatment options are established once patients with CRPC 
progress. Moreover, docetaxel as an anti-microtubule drug has its limitations, 
including drug resistance and side effects caused by drug-binding site mutations on 
β-tubulin 6, overexpression of P-glycoprotein 7 and β-tubulin 8, and neurotoxicity 9. 
Therefore, there is an urgent need to develop alternative treatment strategies. 
 
Eg5, also known as kinesin spindle protein 
10
, is a member of the kinesin-5 motor 
proteins, and plays a crucial role in bipolar spindle formation and duplicated 
chromosome separation during the early phase of mitosis 
11,12
. Inhibition of Eg5 can 
arrest dividing cells in mitosis followed by cell death, without affecting the function 
of interphase microtubules 
13
, thus offering an encouraging alternative to 
microtubule-targeted cancer chemotherapy. The first Eg5-specific inhibitor was 
identified in 1999 on the basis of phenotype-screening, and named monastrol because 
it can induce monoastral spindle formation 
12
. Inactivation of Eg5 cannot cause 
peripheral neuropathy because of Eg5 localization to mitotic spindle microtubules but 
not to interphase microtubules 
14
. Eg5 inhibitors can overcome multidrug resistance to 
taxanes caused by overexpression of P-glycoprotein because Eg5 cannot be 





, a derivative of S-trityl-L-cysteine (STLC) 
18
, can specifically inhibit 
Eg5, as does STLC 
19
, and induce monopolar mitotic spindle formation, but it is more 
than 10 times as potent as STLC 
17
. Meanwhile, the functionalized indoles, such as 
KPYC10665 (2-(trifluoromethyl)-9H-carbazole), KPYC10666 
(2-(tert-butyl)-9H-carbazole) and KPYC10728 
(7-(trifluoromethyl)-9H-pyrido[3,4-b]indole), which are synthesized by one-pot 
N-arylation-oxidative biaryl coupling of anilines and phenyl triflates 
20




In our previous study, S(MeO)TLC displayed its potent anticancer efficacy in 
bladder cancer in vitro and in vivo 
22
. In the present study, we examined Eg5 
expression in prostate cancer cells. We also analyzed the relationship between Eg5 
expression in clinical samples and clinicopathological characteristics. We assessed the 
potent anticancer efficacy of S(MeO)TLC both in vitro and in vivo. 
 Materials and methods  
 
Cell culture and drug compounds  
The prostate cancer cell lines PC3, DU145 and LNCaP were obtained from the 
American Type Culture Collection (ATCC; Rockville, MD, USA). PC3
Luc
 cell line 
was also constructed and used. PC3 cells were lipofected with pGL3-control plasmid 
vector (firefly luciferase gene; Promega, Madison, WI, USA) and pSV2Neo plasmid 




The clone that 
stably expressed strongest luciferase activity was designated PC3
Luc
. The cells were 
routinely propagated in RPMI 1640 supplemented with 10% fetal bovine serum and 
1% penicillin/streptomycin, and incubated at 37°C with a humidified 5% CO2 
atmosphere. 
Five Eg5 inhibitors were used in our study. KPYC10665, KPYC10666 and 
KPYC10728 were synthesized in our institute, and STLC and S(MeO)TLC were 
purchased from Bachem (Bubendorf, Switzerland). All compounds were dissolved in 
DMSO and stored at –20°C.  
 
Eg5 expression in prostate cancer tissue microarrays (TMAs) and cells 
After obtaining approval from the Institutional Review Board at Kyoto University 
Hospital and informed consent, a total of 80 archival specimens of clinically localized 
prostate cancer patients who underwent radical prostatectomy at our institute were 
used in the study. TMAs were constructed from these specimens as previously 
described 
24
. Standard indirect immunoperoxidase assays using primary anti-Eg5 
rabbit antibody (1:300; Cytoskeleton, Denver, CO, USA) were performed to detect 
Eg5 antigen.
 
Eg5 immunostaining was considered positive if the cytoplasm of ≥ 5% 
cancer cells showed weak or greater intensity. Ki67 labeling index was determined as 
previously described 
24
. All pathological evaluations were performed independently 
by two of the authors (N.X. and T.K.). Assessment of Gleason grading and cancer 
staging were based on standard hematoxylin and eosin (H&E) staining and clinical 
data according to the 2002 American Joint Committee on Cancer TNM classification 
and the Japanese General Rules for Clinical and Pathological Studies on Prostate 
cancer (third edition) 
25,26
. The correlation between clinicopathological characteristics 
and Eg5 immunohistological expression was analyzed statistically. 
Eg5 expression in prostate cancer cell lines was determined by western blot 




Briefly, 25 µg protein 
extracts were added to each lane and separated by SDS-PAGE (30 mA for 120 min), 
then blotted onto a polyvinylidene difluoride membrane (16 V for 120 min). After 
incubated with 5% non-fat dry milk for an hour at room temperature, membranes 
were incubated with rabbit primary antibody (1:1 000; Cytoskeleton) for Eg5 
detection and anti-β-actin mouse antibody (1:20 000; Abcam, Cambridge, UK), which 
was employed as an internal control. After incubation with corresponding horseradish 
peroxidase-conjugated secondary antibodies (anti-rabbit, 1:25 000; anti-mouse, 1:10 
000), ECL solution (GE healthcare, Buckinghamshire, UK) was applied to react with 
the membranes and reactive bands were imaged by a PhosphorImager (GE Healthcare, 
Buckinghamshire, UK). 
 
Cell viability assay 
Cell viability was determined using the 3-(4, 5-dimethylthiazol-2-yl)-2, 





grown in 96-well plates at a density of 2.5 × 10
3 
cells per well and incubated for 24 h. 
After that, cells were administered varying concentrations of Eg5 inhibitors, or 
DMSO alone as a control, for additional 72 h incubation. The concentrations of 50% 
cell growth inhibition (IC50) were assessed according to the dose–response curve. 
 






Flow cytometry assay and Hoechst staining 
To assess the cell cycle distribution, DNA content of PC3 cells treated with 
S(MeO)TLC or vehicle was stained by 7-amino-actinomycin D (BD Biosciences, 





least 10 000 cells, including floating and attached cells, were collected and analyzed 
by using a FACSCalibur flow cytometer and CellQuest software (BD Biosciences).
 
Nuclei of the control and treated cells were stained with 1 mM Hoechst 33342 
solution (Wako, Osaka, Japan). The typical morphological changes of apoptotic cells, 
such as condensation and fragmentation of the nuclei, were visualized and identified 
with a fluorescence microscope (Biozero; Keyence, Osaka, Japan).  
 Immunocytofluorescent staining 
To observe microtubules, 1 × 10
5 
PC3 cells treated with S(MeO)TLC for 16 h or 
vehicle alone were fixed and incubated with rabbit anti-α-tubulin primary antibody 
(Cell Signaling Technology, Boston, MA, USA), followed by 
tetramethylrhodamine-isothiocyanate-conjugated polyclonal swine anti-rabbit IgG 
(Dako, Glostrup, Denmark). Vectashield Hard Set Mounting Medium with 4,6- 
diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA, USA) was 
added for counterstaining of nuclei. Fluorescent microscopic images were acquired 
using a fluorescence microscope (Biozero; Keyence, Osaka, Japan), and false color 
(green) was used for nuclei.  
 
Prostate cancer tumor xenograft studies 
Exponentially growing PC3
luc
 cells (5 × 10
6
 cells for one tumor) suspended in 200 μL 
PBS were injected subcutaneously into both flanks of 6-week-old male nude mice 
(BALB/c AJcI-nu/nu; Japan CLEA, Osaka, Japan). The tumor volume was computed 
as: volume = length × width
2 
× 0.5236. When the tumor volume reached ~70 mm
3
, 12 
mice were randomly divided into three groups and treated by daily intraperitoneal 
injection with 10 or 20 mg kg
–1
 S(MeO)TLC or vehicle alone for 5 days. Tumor 
volume and mouse body weight were monitored every other day. On the day 24 after 
the first treatment, all mice were sacrificed. Tumors were excised, weighed, 
formalin-fixed and H&E-stained for histological analysis. Tumors from two mice in 
each group that were sacrificed at 24 h after 5 days treatment with S(MeO)TLC or 
vehicle alone were also formalin-fixed and analyzed histologically using H&E 
staining. Mice were kept under specific pathogen-free conditions, and all animal 
experiments were approved by the Committee on Animal Research at our institute. 
 
Statistical analysis 
SPSS 16.0 software (Chicago, IL, USA) was utilized for statistical analysis. Statistical 
significance was defined as P < 0.05. Two-tailed tests were used. In analysis of TMAs, 
the differences in age, prostate-specific antigen (PSA), Ki-67 labeling index (Ki67 LI) 
between Eg5-positive and -negative groups were analyzed using the Mann–Whitney 
U test. The correlation of Eg5 expression and Gleason score, pathological T stage, and 
positive surgical margin (PSM) was conducted by χ2 test or Fisher exact test. The 
mean subcutaneous tumor volumes, tumor weights and body weights between groups 
at the end of observation were compared using one-way ANOVA. The least squares 
method was used to evaluate the difference between each two groups when ANOVA 
was significant (P < 0.05).  
 
Results 
Expression of Eg5 in prostate cancer 
We evaluated Eg5 expression in prostate cancer cell lines using western blot analysis. 
Eg5 expression was identified in all three cell lines, LNCaP, PC3 and DU145 (Figure 
1A). We investigated Eg5 expression in prostate cancer clinical samples by 
immunohistochemistry using TMAs. Eg5 immunostaining was mainly observed in the 
cytoplasm (Figure 1B). As shown in Table 1, more than half (55.6%, 44/80) of 
prostate cancer clinical specimens exhibited Eg5 expression. Statistical analysis 
revealed that Eg5 expression was significantly associated with Ki67 LI (P = 0.004), 
although there were no significant relationships between Eg5 expression and the other 
clinicopathological parameters (P > 0.05).  
 
Anti-proliferative activity of Eg5 inhibitors against prostate cancer cells 
In our study, the anti-proliferative activity of five Eg5 inhibitors on prostate cancer 
cells was assessed using MTT assay. As shown in Figure 2A and Table 2, the IC50 
(95% CI) of KPYC10665, KPYC10666, KPYC10728, STLC and S(MeO)TLC on 
PC3 cells was 6.54 (6.13–6.98) μM, 6.78 (6.21–7.37) μM, 1.44 (1.23–1.67) μM, 1.10 
(0.93–1.32) μM, and 0.107 (0.081–0.137) μM, respectively. All these five Eg5 
inhibitors had anticancer effects on PC3 cells. S(MeO)TLC exhibited the most 
efficient anticancer activity, with an IC50 that was at least 10-fold lower than that of 
the other agents. Similar results were obtained in DU145 cells (Table 2). S(MeO)TLC 
also showed a strong inhibitory effect on LNCaP cells (data not shown). Trypan blue 
staining (Figure 2B) showed that viability of PC3 cells treated with 500 nM 
S(MeO)TLC for 48 h decreased significantly in comparison with the controls (t test, P 
< 0.01). 
MTT assay and trypan blue staining verified that Eg5 inhibitors can substantially 
inhibit prostate cancer cell proliferation and promote cell death. To explore the 
mechanism by which S(MeO)TLC exerts its anti-proliferative activity in prostate 
cancer cell lines, the cell cycle distribution analysis was performed by flow cytometry 
(Figure 3A and 3B). Compared with the control, the G2/M phase of PC3 cells after 
treatment with 500 nM S(MeO)TLC increased considerably. The percentage of 
mitotic cells reached a peak after 16 h of treatment (G2/M phase cells, 92.1 ± 4.3%). 
After mitotic arrest, the proportion of apoptotic cells (subG1) increased to 2.3 ± 0.5% 
and 15.5 ± 2.4%, after 24 h and 48 h treatment, respectively. Hoechst 33342 staining 
revealed that a majority of monopolar spindle cells arrested in mitosis were observed 
at 16 h after treatment with S(MeO)TLC, and typical nuclear morphological changes 
of apoptotic cells with condensation and fragmentation of the nuclei were also 
identified at 48 h after treatment (Figure 3C). Cells with apoptotic morphology 
increased significantly after 48 h treatment (Figure 3D, P < 0.05). The distinctive 
monopolar spindle morphology with a rosette-like phenotype induced by S(MeO)TLC 
was further visualized by immunofluorescence assay (Figure 3E), and such cells also 
increased significantly after 16 h treatment (Figure 3F, P < 0.01). Collectively, these 
data confirmed that the anti-proliferative activity of S(MeO)TLC in prostate cancer 
cells is induced by mitotic arrest followed by apoptosis. 
 
Efficacy of S(MeO)TLC in the prostate cancer xenograft model 
Our previous study showed that S(MeO)TLC (400 μg kg–1 to 20 mg kg–1) exhibited 
significant anticancer efficacy (P < 0.05) in the human bladder cancer (KU7) 
subcutaneous xenograft models in a dose-dependent manner 
22
. Also, there was no 
significant difference (P > 0.05) in tumor growth between the 20 and 30 mg kg
–1
 
groups. Among the five Eg5 inhibitors tested, S(MeO)TLC was the most effective one 
for the inhibition of KU7 xenograft tumor growth, and the IC50 of S(MeO)TLC on 
KU7 and PC3 cells was almost the same. Therefore, in our present study, we only 
evaluated the anticancer efficacy of S(MeO)TLC in PC3
luc
 subcutaneous xenograft 
models using doses of 10 and 20 mg kg
–1
 and an equal amount of vehicle as a control. 
As shown in Figure 4A, on day 24 after the first treatment, S(MeO)TLC considerably 
inhibited subcutaneous tumor growth in a dose-dependent manner (P < 0.05). At the 
end of the observation, we also compared mean final tumor weights between 
treatment and control groups. The data confirmed that difference in the mean final 
tumor weights between the two groups was statistically significant (Figure 4B, P < 
0.05). No obvious body weight changes and other toxic events such as motor disorder 
and mortality were seen in any group (data not shown). The microscopic appearance 
of the tumors is shown in Figure 4C. Characteristic monopolar spindle mitotic cells 
were observed in H&E-stained tumors from the S(MeO)TLC-treated mice, but not in 
the control group (Figure 4C). 
 
Discussion 
Cancer cells enter into the cell cycle and undergo uncontrolled mitosis permanently, 
which results in unlimited tumor growth. Thus, drugs that interfere with mitosis have 
emerged as the most successful chemotherapeutic agents in clinical use today 
29,30
. 
Among them, anti-microtubule agents, including taxanes and vinca alkaloids that 
disturb microtubule dynamics of mitosis, represent the most effective anticancer drugs 
29,30
. Given the success of taxanes in cancer therapy by perturbing mitosis, Eg5, which 
is more highly expressed in proliferating tissues during mitosis 
31
, is considered as an 
attractive target for cancer chemotherapy.  
Accumulating evidence also indicates that Eg5 inhibition is especially relevant in 
the treatment of CRPC. In addition to sharing the target molecules with taxanes, Eg5 
inhibitors can also exhibit powerful anticancer activity in taxol-resistant cancer cells, 
and they can overcome taxane resistance 
16
. In addition, they can overcome 
taxane-related peripheral neurotoxicity 
13,32
. It has been also reported that, in 
androgen-independent progression of prostate cancer cells, the androgen receptor 
distinctly upregulates M-phase cell-cycle genes to promote androgen-independent cell 
proliferation 
33
. These observations provide us with a strong rationale to utilize Eg5 
inhibitors in the treatment of CRPC.  
In the present study, we found a correlation between Eg5 immunohistological 
expression and clinicopathological characteristics, using TMAs of prostate cancer 
clinical specimens. Although Eg5 expression was not significantly (P > 0.05) 
associated with age, initial PSA, pathological T stage, positive surgical margin status, 
nor Gleason score, we did observe a significant correlation (P = 0.004) between Eg5 
expression and Ki67 LI (the proliferation marker), which is consistent with 
preferential expression of Eg5 in proliferating tissues 
31
. Furthermore, more than half 
the prostate cancer specimens showed Eg5 expression. Meanwhile, western blotting 
analysis showed that Eg5 expression was also present in all three prostate cancer cell 
lines, LNCaP, PC3 and DU145. To summarize, Eg5 could be a potential molecular 
target in prostate cancer chemotherapy. 
To the best of our knowledge, there have been two systematic studies involving 
Eg5 inhibition in prostate cancer 
34,35
. These have revealed that docetaxel-resistant 
and non-resistant prostate cancer cell lines showed almost the same sensitivity to 
antisense oligonucleotide or STLC treatment 
34
. In contrast to the antisense 
oligonucleotide and STLC used in those two studies, in our previous study, our target 
Eg5 inhibitor, S(MeO)TLC (20 µM), was at least 10-fold more potent for inhibition of 
cell proliferation, and was extremely specific to Eg5, without affecting other 
structurally and functionally related mitotic kinesins 
17
. Furthermore, our current 
study confirmed that S(MeO)TLC exhibited more efficient anti-proliferative activity 
compared with STLC and the other three newly synthesized agents 
19
. Thereafter, the 
mechanism of cell growth inhibition in prostate cancer cell lines caused by 
S(MeO)TLC treatment was clarified. S(MeO)TLC exerted its anti-proliferative effect 
by arresting cell-cycle progression at the G2/M phase, with a distinctive monopolar 
spindle phenotype and a rosette-like chromosomal arrangement. Besides, the 
discovery of such a distinctive monopolar spindle phenotype validates the specificity 
of S(MeO)TLC for Eg5 inhibition and the indispensable role of Eg5 in bipolar spindle 
formation. Thus, cancer cell death induced by S(MeO)TLC treatment was provoked 
principally by prolonged mitotic arrest in a time-dependent manner.  
 In view of the potent anticancer efficacy of S(MeO)TLC in vitro, its inhibitory 
effect in subcutaneous xenograft tumor models was further assessed. As expected, 
S(MeO)TLC displayed its significant dose-dependent antitumor efficacy in vivo (P < 
0.05). In addition, the histological observation of characteristic mitotic cells with 
monopolar spindle phenotype suggested that S(MeO)TLC treatment resulted in an 
antitumor effect through induction of mitotic arrest.  
In summary, Eg5 could be a good target for prostate cancer chemotherapy. We 
demonstrated that S(MeO)TLC, as a novel Eg5 inhibitor, exhibited significant 
anticancer efficacy (P < 0.05) in prostate cancer both in vitro and in vivo. In 
consideration of the robust preclinical anticancer attributes of S(MeO)TLC, we 
believe that S(MeO)TLC might exhibit promising clinical efficacy in prostate cancer. 
Further evaluations of the safety of S(MeO)TLC in prostate cancer patients and 
combination chemotherapy should be made before its clinical application. 
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